Literature DB >> 12699587

Effect of exogenous human sodium iodide symporter expression on growth of MATLyLu cells.

Krista M D La Perle1, Eric A G Blomme, Charles C Capen, Sissy M Jhiang.   

Abstract

The sodium iodide symporter (NIS) mediates iodide uptake in thyroid cells and enables the effective radioiodide treatment of thyroid cancers. There is much interest in facilitating radioiodide therapy in other cancers by NIS gene transfer. This study showed that exogenous NIS expression decreased MATLyLu rat prostatic adenocarcinoma cell growth. Tumor growth and metastatic progression were significantly delayed in syngeneic rats injected with mixed or clonal populations of MATLyLu-NIS cells compared to rats with control tumors. MATLyLu-NIS tumors in nude mice had a lower, albeit not statistically significant, growth rate than control tumors. The Ki-67 labeling index in NIS-positive areas was lower than in NIS-negative areas of rat tumors derived from a mixed population of MATLyLu-NIS cells. Growth of clonal populations of MATLyLu-NIS cells was delayed in vitro. These results demonstrate that NIS expression inhibits MATLyLu cell growth, thereby providing an additional potential benefit of NIS-mediated gene therapy for cancer.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12699587     DOI: 10.1089/105072503321319431

Source DB:  PubMed          Journal:  Thyroid        ISSN: 1050-7256            Impact factor:   6.568


  3 in total

1.  Efficacy of 99mTc pertechnetate and 131I radioisotope therapy in sodium/iodide symporter (NIS)-expressing neuroendocrine tumors in vivo.

Authors:  Meike L Schipper; Christoph G U Riese; Stephan Seitz; Alexander Weber; Martin Béhé; Tino Schurrat; Nils Schramm; Boris Keil; Heiko Alfke; Thomas M Behr
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-12-08       Impact factor: 9.236

Review 2.  Sodium iodide symporter and the radioiodine treatment of thyroid carcinoma.

Authors:  June-Key Chung; Hye Won Youn; Joo Hyun Kang; Ho Young Lee; Keon Wook Kang
Journal:  Nucl Med Mol Imaging       Date:  2010-02-26

3.  A whole-body dual-modality radionuclide optical strategy for preclinical imaging of metastasis and heterogeneous treatment response in different microenvironments.

Authors:  Gilbert O Fruhwirth; Seckou Diocou; Philip J Blower; Tony Ng; Greg E D Mullen
Journal:  J Nucl Med       Date:  2014-03-06       Impact factor: 10.057

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.